Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy

Ahizechukwu C. Eke, Jiajia Wang, Khadija Amin, David E. Shapiro, Alice Stek, Elizabeth Smith, Nahida Chakhtoura, Michael Basar, Kathleen George, Katherine M. Knapp,

Antimicrobial Agents and Chemotherapy · 2020 · 11 citations · 23 references

DOIFull text

Open access

Concepts

Abstract

The purpose of this study was to evaluate the pharmacokinetics of ritonavir-boosted fosamprenavir during pregnancy and postpartum. Amprenavir (the active moiety of fosamprenavir) and ritonavir intensive pharmacokinetic evaluations were performed at steady state during the second and third trimesters of pregnancy and postpartum. Plasma concentrations of amprenavir and ritonavir were measured using high-performance liquid chromatography. The target amprenavir area under the concentration-versus-time curve (AUC) was higher than the 10th percentile (27.

References

23